论文部分内容阅读
糖化血红蛋白(GHb)是血液中葡萄糖与血红蛋白结合形成的产物,通过与红细胞内非酶作用与一链缬氨酸结合而成。糖化血红蛋白A1c(HbA1c)与红细胞生命周期相关,可以反应患者近2—3个月的血糖总水平,已被临床视为评估糖尿病(DM)患者血糖控制水平的相对金标准,HbA1c在美国已成为糖尿病的一种诊断方法,美国糖尿病协会(ADA)在其《2011糖尿病诊疗指南》及同期发布的《糖尿病诊断和分类》中均确定其诊断界值为6.5%。糖尿病在预测心血管意外事件的可靠性已受到肯定和重视,被看作是冠心病的等危症。HbA1c与糖尿病及心血管病并发症之间存在明显关联,在预测冠心病预后方面,具有广泛价值。本文就HbA1c与急性ST段抬高型心肌梗死(STEMI)的发病、临床转归以及预后之间的关系作一综述。
Glycosylated hemoglobin (GHb) is a product of the combination of glucose and hemoglobin in the blood, which binds to a chain of valine through non-enzymatic action within the red blood cell. Glycated hemoglobin A1c (HbA1c), which correlates with the life cycle of erythrocytes, reflects the overall blood glucose level in patients for nearly 2-3 months and has been clinically considered the relative gold standard for assessing glycemic control in diabetic patients. HbA1c has become Diabetes diagnosis, the American Diabetes Association (ADA) in its “2011 Guide to Diabetes Diagnosis and Treatment” and the simultaneous release of “Diabetes Diagnosis and Classification” were identified as the diagnostic threshold of 6.5%. The reliability of diabetes in predicting cardiovascular accidents has been affirmed and valued, is considered as coronary heart disease and other crisis. There is a clear correlation between HbA1c and complications of diabetes mellitus and cardiovascular disease, which has a wide range of value in predicting the prognosis of coronary heart disease. This article reviews the relationship between HbA1c and the incidence, clinical outcome, and prognosis of acute ST-segment elevation myocardial infarction (STEMI).